- Home
- NCNA vs VRAX Comparison
NCNA vs VRAX Comparison
Compare NCNA & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCNA
- VRAX
- Stock Information
- Founded
- NCNA 1997
- VRAX 2013
- Country
- NCNA United Kingdom
- VRAX United Kingdom
- Employees
- NCNA N/A
- VRAX N/A
- Industry
- NCNA Biotechnology: Pharmaceutical Preparations
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NCNA Health Care
- VRAX Health Care
- Exchange
- NCNA Nasdaq
- VRAX Nasdaq
- Market Cap
- NCNA 4.5M
- VRAX 4.7M
- IPO Year
- NCNA 2017
- VRAX 2022
- Fundamental
- Price
- NCNA $0.05
- VRAX $0.91
- Analyst Decision
- NCNA Buy
- VRAX Strong Buy
- Analyst Count
- NCNA 2
- VRAX 1
- Target Price
- NCNA $25.00
- VRAX $3.00
- AVG Volume (30 Days)
- NCNA 208.6M
- VRAX 46.8K
- Earning Date
- NCNA 08-14-2025
- VRAX 02-05-2025
- Dividend Yield
- NCNA N/A
- VRAX N/A
- EPS Growth
- NCNA N/A
- VRAX N/A
- EPS
- NCNA N/A
- VRAX N/A
- Revenue
- NCNA N/A
- VRAX $6,331.00
- Revenue This Year
- NCNA N/A
- VRAX $217,274.83
- Revenue Next Year
- NCNA N/A
- VRAX N/A
- P/E Ratio
- NCNA N/A
- VRAX N/A
- Revenue Growth
- NCNA N/A
- VRAX N/A
- 52 Week Low
- NCNA $0.03
- VRAX $0.74
- 52 Week High
- NCNA $10.79
- VRAX $9.00
- Technical
- Relative Strength Index (RSI)
- NCNA 38.50
- VRAX 50.78
- Support Level
- NCNA $0.05
- VRAX $0.84
- Resistance Level
- NCNA $0.13
- VRAX $0.99
- Average True Range (ATR)
- NCNA 0.02
- VRAX 0.07
- MACD
- NCNA 0.00
- VRAX 0.02
- Stochastic Oscillator
- NCNA 4.62
- VRAX 60.20
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.